- Company
- Chong Kun Dang co-market Xofluza with Roche
- by Chon, Seung-Hyun Mar 23, 2020 06:27am
- Chong Kun Dang announced on the 19th that it recently signed a joint sales contract with Roche Korea for domestic distribution of the influenza treatment drug 'Xofluza'. Roche Korea and Chong Kun Dang jointly handle marketing and sales of Xofluza, and Chong Kun Dang is responsible for distribution. Xofluza is a drug used to treat influe
- Policy
- IMD Vildagle to receive reimbursed price of KRW 403
- by Kim, Jung-Ju Mar 23, 2020 06:27am
- Hanmi Pharmaceutical’s dipeptidyl peptidase-4 (DPP-4) inhibiting diabetic treatment Vildagle 50 mg tablet (vildagliptin hydrochloride) would receive health insurance reimbursement from next month. The treatment is an incrementally modified drug (IMD) of Galvus tablet (vildagliptin) that evaded the original’s patent, and it would be listed
- Policy
- Revised generic reimbursement regulation to get delayed
- by Lee, Hye-Kyung Mar 23, 2020 06:27am
- Apparently, the postponed action plan on the revised reimbursed generic pricing management, covering all procedures of the listing, would also likely to affect drug pricing negotiation schedule. As the Korea’s Ministry of Health and Welfare (MOHW) is preoccupied with response against COVID-19 outbreak and the main division director’s p
- Why rapid diagnostic kit for COVID-19 is not used in korea?
- by 박상준 Mar 23, 2020 06:27am
- “The current diagnosis method of COVID-19 is as if there are two diagnostic methods, MRI and X-ray, and it is said to use only MRI. Even when it takes a lot of time and money”. This is a metaphor for the reality that the Korea Small and Medium Hospital Association's Chairman Sang-il Kim (President H Plus Yangji Hospital), which is currently
- Policy
- The Review Committee for Cancer Diseases postponed again
- by Kim, Jung-Ju Mar 20, 2020 06:27am
- COVID-19 crisis that spread around the world is prolonged and the face-to-face meeting of the Review and Assessment Committees within HIRA is also changing by choosing the second-best solution. Last month and this month, when the spread of infectious diseases in Korea was at the forefront, once it was postponed or canceled, it was no long
- Policy
- Imfinzi available for reimbursed use from next month
- by Lee, Hye-Kyung Mar 20, 2020 06:25am
- From next month, reimbursed use of Imfinzi (durvalumab) would be available for non-small cell lung cancer (NSCLC) monotherapy. The new reimbursement standard set for Imfinzi would enable administering immunotherapy not only for palliative chemotherapy, but also as consolidation therapy. The reimbursement standard would be also applicable
- Company
- Daewoong vs Allergan, patent dispute for two years
- by Kim, Jin-Gu Mar 20, 2020 06:25am
- The patent dispute between Daewoong Pharmaceutical and Allergan surrounding double-chin reduction treatment 'Belkyra' has not been concluded for the second year. According to the pharmaceutical industry on the 19th, the dispute began in March 2018, two years ago. Daewoong Pharmaceutical filed an invalidation trial of patents for Belkyra
- No need to change antihypertensive drugs due to COVID-19
- by Lee, In Bok Mar 20, 2020 06:25am
- The Korean Society of Hypertension agrees to causality through a statement, although some claims have been made that the representative hypertensive drugs, Angiotensin Receptor Blocker (ARB) and Angiotensin Converting Enzyme Inhibitor (ACEI), may exacerbate COVID-19 symptoms. It was recommended that the current prescription should be maintained
- Rosuzet and Tagrisso prescription soar amid COVID-19
- by Chon, Seung-Hyun Mar 20, 2020 06:25am
- Amid medical chaos caused by the 2019 novel coronavirus (COVID-19), outpatient prescription market has fluctuated dramatically. The prescription volumes of anticancer Tagrisso and cholesterol-lowering combination drug Rosuzet have apparently skyrocketed. Whereas off-patent drugs like Lipitor, Plavix and Crestor that used to show significant
- Policy
- New reimbursed price for Imfinzi, Venclaxta and Blincyto
- by Kim, Jung-Ju Mar 20, 2020 06:25am
- From next month, health insurance reimbursement would be granted on AstraZeneca Korea’s locally advanced non-small cell lung cancer (NSCLC) treatment Imfinzi (durvalumab) and AbbVie Korea’s chronic lymphocytic leukemia (CLL) treatment Venclaxta (venetoclax). Two treatments have accepted risk sharing agreement (RSA) terms set down on the
